INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41701, 1744, 'Codeine', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41702, 1744, 'Codeine', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41703, 1744, 'Codeine', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41704, 1744, 'Codeine', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41705, 0, 'Cobimetinib', 'Cardiomyopathies', 'Cardiomyopathy, defined as symptomatic and asymptomatic decline in left ventricular ejection fraction (LVEF), can occur with the use of cobimetinib.  Evaluate LVEF prior to, 1 month after initiation, and every 3 months thereafter until discontinuation of cobimetinib.  It is recommended to manage events of left ventricular dysfunction through treatment interruption, dose reduction, or discontinuation of therapy.  If restarting cobimetinib after a dose reduction or interruption it is recommended to evaluate LVEF as clinically indicated.  Care should be exercised when using cobimetinib as the safety of cobimetinib has not been established in patients with a baseline LVEF that is either below institutional lower limit of normal (LLN) or below 50%.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41706, 0, 'Cobimetinib', 'Liver Diseases', 'Hepatotoxicity can occur with the use of cobimetinib.  It is recommended to monitor liver function tests before initiation of therapy, monthly during treatment, or more frequently as clinically indicated.  Manage Grade 3 and 4 liver laboratory abnormalities with dose interruption, reduction, or discontinuation of therapy.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41707, 0, 'Cobimetinib', 'Toxic Optic Neuropathy', 'Ocular toxicities can occur with cobimetinib, including serous retinopathy.  Consider ophthalmologic examinations including retinal evaluation before treatment and at regular intervals during, and any time a patient reports new or worsening visual disturbances.  If serous retinopathy is diagnosed, interrupt treatment with cobimetinib until visual symptoms improve.  Manage serous retinopathy with treatment interruption, dose reduction, or with treatment discontinuation.  Close monitoring is recommended.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41708, 0, 'Cobimetinib', 'Rhabdomyolysis', 'Rhabdomyolysis can occur with the use of cobimetinib.  It is recommended to obtain baseline serum creatine phosphokinase (CPK) and creatinine levels prior to initiating therapy with cobimetinib and periodically during treatment as clinically indicated.  If CPK is elevated, evaluate for signs and symptoms of rhabdomyolysis or other causes.  Depending on the severity of symptoms or CPK elevation, dose interruption or discontinuation may be required.  Care should be taken when using this agent in patients at risk for rhabdomyolysis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41709, 0, 'Cobimetinib', 'Lung Diseases', 'The use of certain multikinase inhibitors has been associated with pulmonary toxicity.  Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported.  Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation.  If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.  Immediately withhold treatment in patients diagnosed with ILD/pneumonitis and permanently discontinue therapy if no other potential causes of ILD/pneumonitis have been identified.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41710, 0, 'Cobimetinib', 'Kidney Diseases', 'The recommended dosage of olutasidenib has not been established in patients with severe renal impairment (CrCl 15 to 29 mL/min), kidney failure, and patients on dialysis.  Caution is advised.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41711, 0, 'Alfentanil', 'Liver Diseases', 'Narcotic (opioid) analgesic agents are extensively metabolized by the liver, and several of them (e.g., codeine, hydrocodone, meperidine, methadone, morphine, propoxyphene) have active metabolites that are further converted to inactive substances.  The serum concentrations of these agents and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with liver disease.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41712, 0, 'Alfentanil', 'Premature Birth', 'The use of narcotic (opioid) analgesic agents is contraindicated in premature infants.  These agents may cross the immature blood-brain barrier to a greater extent than in adults, resulting in disproportionate respiratory depression.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41713, 0, 'Alfentanil', 'Alcoholic Intoxication', 'The use of opiate agonists is contraindicated in patients with acute alcohol intoxication exhibiting depressed vital signs.  The central nervous system depressant effects of opiate agonists may be additive with those of alcohol.  Severe respiratory depression and death may occur.  Therapy with opiate agonists should be administered cautiously in patients who might be prone to acute alcohol intake.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41714, 0, 'Alfentanil', 'Intestinal Obstruction', 'Opioid agonists are contraindicated in patients with known or suspected gastrointestinal obstruction, including paralytic ileus.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41715, 0, 'Alfentanil', 'Hypotension', 'Opiate agonists can induce vasodilation and significant hypotension, particularly when given in high dosages and/or by rapid intravenous administration.  Opiate analgesics cause vasodilatation that may exacerbate hypotension and hypoperfusion and, therefore, are contraindicated in circulatory shock.  At therapeutic analgesic dosages, ambulatory patients are more likely to experience dizziness and hypotension than patients who are confined to bed.  However, orthostatic hypotension may occur in supine patients upon rising.  Therapy with opiate agonists should be administered cautiously and initiated at reduced dosages in patients with hypovolemia, or a predisposition to hypotension.  When given by intramuscular or subcutaneous administration, clinicians should also be aware that impaired perfusion in these patients may prevent complete absorption of the drug.  With repeated injections, an excessive amount may be absorbed suddenly if normal circulation is reestablished.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41716, 0, 'Alfentanil', 'Intracranial Hypertension', 'The hypoventilation associated with administration of opiate agonists, particularly by the intravenous route, can induce cerebral hypoxia and vasodilatation with resultant increase in intracranial pressure.  Opiate agonists should not be used in patients with suspected or known head injury or increased intracranial pressure.  Also, clinicians treating such patients should be aware that opiate agonists may interfere with the evaluation of CNS function, especially with respect to consciousness levels, respiratory status, and pupillary changes.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41717, 0, 'Alfentanil', 'Respiratory Insufficiency', 'Opiate agonists may produce significant central nervous system and respiratory depression of varying duration, particularly when given in high dosages and/or by rapid intravenous administration.  Apnea may result from decreased respiratory drive as well as increased airway resistance, and rigidity of respiratory muscles may occur during rapid IV administration or when these agents are used in the induction of anesthesia.  At therapeutic analgesic dosages, the respiratory effects are usually not clinically important except in patients with preexisting pulmonary impairment.  Therapy with opiate agonists should be avoided or administered with extreme caution and initiated at reduced dosages in patients with severe CNS depression; sleep apnea; hypoxia, anoxia, or hypercapnia; upper airway obstruction; chronic pulmonary insufficiency; a limited ventilatory reserve; or other respiratory disorders.  In the presence of excessive respiratory secretions, the use of opiate agonists may also be problematic because they decrease ciliary activity and reduce the cough reflex.  Caution is also advised in patients who may be at increased risk for respiratory depression, such as comatose patients or those with head injury, intracranial lesions, or intracranial hypertension.  Clinical monitoring of pulmonary function is recommended, and equipment for resuscitation should be immediately available if parenteral or neuraxial routes are used.  Naloxone may be administered to reverse clinically significant respiratory depression, which may be prolonged depending on the opioid agent, cumulative dose, and route of administration.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41718, 0, 'Alfentanil', 'Adrenal Insufficiency', 'Patients with Addison''s disease may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  Conversely, these agents may cause or potentiate adrenal insufficiency.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with adrenocortical insufficiency.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41719, 0, 'Alfentanil', 'Hypothyroidism', 'Patients with hypothyroidism may have increased risk of respiratory depression and prolonged CNS depression associated with the use of narcotic (opioid) analgesic agents.  These agents may also exacerbate the effects of hypothyroidism such as lethargy, impaired mentation, depression, and constipation.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with uncontrolled hypothyroidism or myxedema.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41720, 0, 'Alfentanil', 'Kidney Diseases', 'Although narcotic (opioid) analgesic agents are generally metabolized by the liver, renal impairment can alter the elimination of these agents and their metabolites (some of which are pharmacologically active), resulting in drug accumulation and increased risk of toxicity.  Therapy with opioids should be administered cautiously and initiated at reduced dosages in patients with significantly impaired renal function.  Subsequent doses should be titrated based on individual response rather than a fixed dosing schedule.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41721, 0, 'Alfentanil', 'Epilepsy', 'Narcotic (opioid) analgesic agents may exacerbate seizures in patients with seizure disorders and, at higher dosages, have been reported to induce seizures in patients without previous history of seizures.  The proconvulsant activity may be the greatest with meperidine, the active metabolite of which is thought to be responsible.  Therapy with opioids should be administered cautiously in patients with or predisposed to seizures.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41722, 0, 'Alfentanil', 'Urinary Retention', 'Narcotic (opioid) analgesic agents may inhibit the urinary voiding reflex and increase the tone of the vesical sphincter in the bladder.  Acute urinary retention requiring catheterization may occur, particularly in patients with prostatic hypertrophy or urethral stricture and in elderly patients.  These agents may also decrease urine production via direct effects on the kidney and central stimulation of the release of vasopressin.  Therapy with opioids should be administered cautiously in patients with or predisposed to urinary retention and/or oliguria.  The effects on smooth muscle tone appear to be the most pronounced with morphine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41723, 0, 'Alfentanil', 'Arrhythmias, Cardiac', 'Opiate agonists have cholinergic activity.  Large doses and/or rapid intravenous administration may produce bradycardia and arrhythmia via stimulation of medullary vagal nuclei.  Unlike other agents in the class, meperidine also has anticholinergic activity and may cause either bradycardia or tachycardia.  Therapy with opiate agonists should be administered cautiously in patients with a history of arrhythmias.  Clinical monitoring of cardiovascular status is recommended during therapy.  Bradycardia and other cholinergic effects produced by these agents may be controlled with atropine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41724, 0, 'Colestipol', 'Cholestasis', 'The use of bile acid sequestrants is contraindicated in patients with complete biliary obstruction where bile is not secreted into the intestine.  These agents adsorb and combine with bile acids in the intestine to form an insoluble complex that is excreted in the feces, resulting in partial removal of bile acids from the enterohepatic circulation.  Bile acid sequestrants are ineffective if bile does not reach the intestine.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41725, 0, 'Colestipol', 'Constipation', 'The use of bile acid sequestrants may produce or worsen preexisting constipation.  Constipation associated with these agents may aggravate hemorrhoids.  Therapy with bile acid sequestrants should be administered cautiously in patients with preexisting constipation, hemorrhoids, or symptomatic coronary artery disease.  The dosage should be increased very gradually according to manufacturer guidelines to minimize the risk of fecal impaction, and patients should be encouraged to increase fluid and fiber intake.  Occasional use of a stool softener may also be indicated.  If constipation worsens or develops during therapy, or the desired therapeutic response is not achieved at the maximum recommended daily dosage, combination therapy or an alternative agent should be considered.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41726, 0, 'Colestipol', 'Acidosis', 'Bile acid sequestrants are chloride forms of anion exchange resins and may produce hyperchloremic acidosis with chronic use.  Therapy with bile acid sequestrants should be administered cautiously in patients who may be particularly susceptible, including children or smaller patients and patients with renal impairment or volume depletion.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41727, 0, 'Colestipol', 'Phenylketonurias', 'Questran Light and LoCholest Light (brands of cholestyramine) contain 16.8 mg and 22.4 mg of phenylalanine, respectively, per each dose.  Flavored Colestid (brand of colestipol) contains 18.2 mg of phenylalanine per each 7.5-gram dose.  WELCHOL (brand name of colesevelam) for Oral Suspension contains 13.5 mg phenylalanine per 1.875 gram dose and 27 mg phenylalanine per 3.75 gram dose.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).  Regular Colestid, Questran and LoCholest do not contain phenylalanine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41728, 0, 'Colestipol', 'Nutrition disorder', 'Bile acid sequestrants may interfere with the absorption of folic acid and fat soluble vitamins such as A, D, and K.  Chronic use of bile acid sequestrants may cause increased bleeding tendency due to hypoprothrombinemia associated with vitamin K deficiency.  Anemia may also occur due to reduced serum or red blood cell folate.  Supplementation with oral vitamins and/or folate should be considered during prolonged therapy with bile acid sequestrants, particularly in patients with preexisting vitamin and/or folate deficiencies, anemia, or a bleeding diathesis.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41729, 2886, 'Colchicine', 'Bone Marrow Failure Disorders', 'The use of colchicine should be used with caution in patients with bone marrow suppression.  Patients on long term therapy may require periodic blood counts.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41730, 7714, 'Colchicine', 'Bone Marrow Failure Disorders', 'The use of colchicine should be used with caution in patients with bone marrow suppression.  Patients on long term therapy may require periodic blood counts.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41731, 7718, 'Colchicine', 'Bone Marrow Failure Disorders', 'The use of colchicine should be used with caution in patients with bone marrow suppression.  Patients on long term therapy may require periodic blood counts.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41732, 16617, 'Colchicine', 'Bone Marrow Failure Disorders', 'The use of colchicine should be used with caution in patients with bone marrow suppression.  Patients on long term therapy may require periodic blood counts.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41733, 16618, 'Colchicine', 'Bone Marrow Failure Disorders', 'The use of colchicine should be used with caution in patients with bone marrow suppression.  Patients on long term therapy may require periodic blood counts.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41734, 16651, 'Colchicine', 'Bone Marrow Failure Disorders', 'The use of colchicine should be used with caution in patients with bone marrow suppression.  Patients on long term therapy may require periodic blood counts.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41735, 30612, 'Colchicine', 'Bone Marrow Failure Disorders', 'The use of colchicine should be used with caution in patients with bone marrow suppression.  Patients on long term therapy may require periodic blood counts.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41736, 2886, 'Colchicine', 'Heart Failure', 'The use of colchicine should be used with caution in patients with cardiac dysfunction.  The possibility of cumulative effects of colchicine is increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41737, 7714, 'Colchicine', 'Heart Failure', 'The use of colchicine should be used with caution in patients with cardiac dysfunction.  The possibility of cumulative effects of colchicine is increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41738, 7718, 'Colchicine', 'Heart Failure', 'The use of colchicine should be used with caution in patients with cardiac dysfunction.  The possibility of cumulative effects of colchicine is increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41739, 16617, 'Colchicine', 'Heart Failure', 'The use of colchicine should be used with caution in patients with cardiac dysfunction.  The possibility of cumulative effects of colchicine is increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41740, 16618, 'Colchicine', 'Heart Failure', 'The use of colchicine should be used with caution in patients with cardiac dysfunction.  The possibility of cumulative effects of colchicine is increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41741, 16651, 'Colchicine', 'Heart Failure', 'The use of colchicine should be used with caution in patients with cardiac dysfunction.  The possibility of cumulative effects of colchicine is increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41742, 30612, 'Colchicine', 'Heart Failure', 'The use of colchicine should be used with caution in patients with cardiac dysfunction.  The possibility of cumulative effects of colchicine is increased in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41743, 2886, 'Colchicine', 'Disseminated Intravascular Coagulation', 'Colchicine should be used with caution in patients with disseminated intravascular coagulation.  Debilitated patients have an increased risk of developing colchicine toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41744, 7714, 'Colchicine', 'Disseminated Intravascular Coagulation', 'Colchicine should be used with caution in patients with disseminated intravascular coagulation.  Debilitated patients have an increased risk of developing colchicine toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41745, 7718, 'Colchicine', 'Disseminated Intravascular Coagulation', 'Colchicine should be used with caution in patients with disseminated intravascular coagulation.  Debilitated patients have an increased risk of developing colchicine toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41746, 16617, 'Colchicine', 'Disseminated Intravascular Coagulation', 'Colchicine should be used with caution in patients with disseminated intravascular coagulation.  Debilitated patients have an increased risk of developing colchicine toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41747, 16618, 'Colchicine', 'Disseminated Intravascular Coagulation', 'Colchicine should be used with caution in patients with disseminated intravascular coagulation.  Debilitated patients have an increased risk of developing colchicine toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41748, 16651, 'Colchicine', 'Disseminated Intravascular Coagulation', 'Colchicine should be used with caution in patients with disseminated intravascular coagulation.  Debilitated patients have an increased risk of developing colchicine toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41749, 30612, 'Colchicine', 'Disseminated Intravascular Coagulation', 'Colchicine should be used with caution in patients with disseminated intravascular coagulation.  Debilitated patients have an increased risk of developing colchicine toxicity.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41750, 2886, 'Colchicine', 'Water-Electrolyte Imbalance', 'Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting.  Therapy with colchicine should be administered with caution in patients with electrolyte imbalances.  Monitoring serum electrolytes is recommended in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41751, 7714, 'Colchicine', 'Water-Electrolyte Imbalance', 'Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting.  Therapy with colchicine should be administered with caution in patients with electrolyte imbalances.  Monitoring serum electrolytes is recommended in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41752, 7718, 'Colchicine', 'Water-Electrolyte Imbalance', 'Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting.  Therapy with colchicine should be administered with caution in patients with electrolyte imbalances.  Monitoring serum electrolytes is recommended in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41753, 16617, 'Colchicine', 'Water-Electrolyte Imbalance', 'Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting.  Therapy with colchicine should be administered with caution in patients with electrolyte imbalances.  Monitoring serum electrolytes is recommended in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41754, 16618, 'Colchicine', 'Water-Electrolyte Imbalance', 'Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting.  Therapy with colchicine should be administered with caution in patients with electrolyte imbalances.  Monitoring serum electrolytes is recommended in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41755, 16651, 'Colchicine', 'Water-Electrolyte Imbalance', 'Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting.  Therapy with colchicine should be administered with caution in patients with electrolyte imbalances.  Monitoring serum electrolytes is recommended in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41756, 30612, 'Colchicine', 'Water-Electrolyte Imbalance', 'Electrolyte imbalances including hypokalemia and hyponatremia may worsen in patients taking colchicine as the most common adverse effects of colchicine include nausea and vomiting.  Therapy with colchicine should be administered with caution in patients with electrolyte imbalances.  Monitoring serum electrolytes is recommended in these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41757, 2886, 'Colchicine', 'Liver Diseases', 'The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject.  No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).  Caution is recommended when prescribing colchicine to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41758, 7714, 'Colchicine', 'Liver Diseases', 'The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject.  No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).  Caution is recommended when prescribing colchicine to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41759, 7718, 'Colchicine', 'Liver Diseases', 'The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject.  No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).  Caution is recommended when prescribing colchicine to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41760, 16617, 'Colchicine', 'Liver Diseases', 'The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject.  No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).  Caution is recommended when prescribing colchicine to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41761, 16618, 'Colchicine', 'Liver Diseases', 'The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject.  No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).  Caution is recommended when prescribing colchicine to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41762, 16651, 'Colchicine', 'Liver Diseases', 'The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject.  No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).  Caution is recommended when prescribing colchicine to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41763, 30612, 'Colchicine', 'Liver Diseases', 'The clearance of colchicine may be significantly reduced and plasma half-life prolonged in patients with chronic hepatic impairment compared to healthy subject.  No pharmacokinetic data are available for patients with severe hepatic impairment (Child-Pugh C).  Caution is recommended when prescribing colchicine to these patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41764, 2886, 'Colchicine', 'Kidney Diseases', 'Colchicine is significantly excreted in urine in healthy subjects.  Clearance of colchicine is decreased in patients with impaired renal function.  Colchicine dosing must be individualized according to the patient''s renal function.  Caution must be exercised when colchicine therapy is instituted in these patients.  Monitoring creatinine function is recommended in patients on long term therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41765, 7714, 'Colchicine', 'Kidney Diseases', 'Colchicine is significantly excreted in urine in healthy subjects.  Clearance of colchicine is decreased in patients with impaired renal function.  Colchicine dosing must be individualized according to the patient''s renal function.  Caution must be exercised when colchicine therapy is instituted in these patients.  Monitoring creatinine function is recommended in patients on long term therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41766, 7718, 'Colchicine', 'Kidney Diseases', 'Colchicine is significantly excreted in urine in healthy subjects.  Clearance of colchicine is decreased in patients with impaired renal function.  Colchicine dosing must be individualized according to the patient''s renal function.  Caution must be exercised when colchicine therapy is instituted in these patients.  Monitoring creatinine function is recommended in patients on long term therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41767, 16617, 'Colchicine', 'Kidney Diseases', 'Colchicine is significantly excreted in urine in healthy subjects.  Clearance of colchicine is decreased in patients with impaired renal function.  Colchicine dosing must be individualized according to the patient''s renal function.  Caution must be exercised when colchicine therapy is instituted in these patients.  Monitoring creatinine function is recommended in patients on long term therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41768, 16618, 'Colchicine', 'Kidney Diseases', 'Colchicine is significantly excreted in urine in healthy subjects.  Clearance of colchicine is decreased in patients with impaired renal function.  Colchicine dosing must be individualized according to the patient''s renal function.  Caution must be exercised when colchicine therapy is instituted in these patients.  Monitoring creatinine function is recommended in patients on long term therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41769, 16651, 'Colchicine', 'Kidney Diseases', 'Colchicine is significantly excreted in urine in healthy subjects.  Clearance of colchicine is decreased in patients with impaired renal function.  Colchicine dosing must be individualized according to the patient''s renal function.  Caution must be exercised when colchicine therapy is instituted in these patients.  Monitoring creatinine function is recommended in patients on long term therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41770, 30612, 'Colchicine', 'Kidney Diseases', 'Colchicine is significantly excreted in urine in healthy subjects.  Clearance of colchicine is decreased in patients with impaired renal function.  Colchicine dosing must be individualized according to the patient''s renal function.  Caution must be exercised when colchicine therapy is instituted in these patients.  Monitoring creatinine function is recommended in patients on long term therapy.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41771, 2886, 'Colchicine', 'Rhabdomyolysis', 'Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses.  Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk.  Caution must be exercised when colchicine therapy is instituted in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41772, 7714, 'Colchicine', 'Rhabdomyolysis', 'Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses.  Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk.  Caution must be exercised when colchicine therapy is instituted in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41773, 7718, 'Colchicine', 'Rhabdomyolysis', 'Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses.  Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk.  Caution must be exercised when colchicine therapy is instituted in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41774, 16617, 'Colchicine', 'Rhabdomyolysis', 'Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses.  Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk.  Caution must be exercised when colchicine therapy is instituted in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41775, 16618, 'Colchicine', 'Rhabdomyolysis', 'Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses.  Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk.  Caution must be exercised when colchicine therapy is instituted in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41776, 16651, 'Colchicine', 'Rhabdomyolysis', 'Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses.  Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk.  Caution must be exercised when colchicine therapy is instituted in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41777, 30612, 'Colchicine', 'Rhabdomyolysis', 'Colchicine-induced neuromuscular toxicity and rhabdomyolysis have been reported with chronic treatment in therapeutic doses.  Patients with renal dysfunction and elderly patients, even those with normal renal and hepatic function, are at increased risk.  Caution must be exercised when colchicine therapy is instituted in these patients.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41778, 14117, 'Colesevelam', 'Diabetic Ketoacidosis', 'Colesevelam should not be used for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41779, 16275, 'Colesevelam', 'Diabetic Ketoacidosis', 'Colesevelam should not be used for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41780, 25347, 'Colesevelam', 'Diabetic Ketoacidosis', 'Colesevelam should not be used for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41781, 14117, 'Colesevelam', 'Gastrointestinal Diseases', 'The manufacturer considers colesevelam contraindicated in patients with a history of bowel obstruction.  Because of its constipating effects, colesevelam is not recommended in patients with gastroparesis, other gastrointestinal motility disorders, and in those who have had major gastrointestinal tract surgery and who may be at risk for bowel obstruction.  Because of the tablet size, colesevelam tablets can cause dysphagia or esophageal obstruction and should be used with caution in patients with dysphagia or swallowing disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41782, 16275, 'Colesevelam', 'Gastrointestinal Diseases', 'The manufacturer considers colesevelam contraindicated in patients with a history of bowel obstruction.  Because of its constipating effects, colesevelam is not recommended in patients with gastroparesis, other gastrointestinal motility disorders, and in those who have had major gastrointestinal tract surgery and who may be at risk for bowel obstruction.  Because of the tablet size, colesevelam tablets can cause dysphagia or esophageal obstruction and should be used with caution in patients with dysphagia or swallowing disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41783, 25347, 'Colesevelam', 'Gastrointestinal Diseases', 'The manufacturer considers colesevelam contraindicated in patients with a history of bowel obstruction.  Because of its constipating effects, colesevelam is not recommended in patients with gastroparesis, other gastrointestinal motility disorders, and in those who have had major gastrointestinal tract surgery and who may be at risk for bowel obstruction.  Because of the tablet size, colesevelam tablets can cause dysphagia or esophageal obstruction and should be used with caution in patients with dysphagia or swallowing disorders.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41784, 14117, 'Colesevelam', 'Hyperlipoproteinemias', 'The manufacturer considers the use of colesevelam to be contraindicated in patients with TG levels >500 mg/dL.  Colesevelam, like other bile acid sequestrants, can increase serum TG concentrations.  Lipid parameters, including TG levels and non-HDL-C, should be obtained before starting colesevelam and periodically thereafter.  Caution should be exercised when treating patients with TG levels greater than 300 mg/dL.  Colesevelam should be discontinued if TG levels exceed 500 mg/dL or if the patient develops hypertriglyceridemia-induced pancreatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41785, 16275, 'Colesevelam', 'Hyperlipoproteinemias', 'The manufacturer considers the use of colesevelam to be contraindicated in patients with TG levels >500 mg/dL.  Colesevelam, like other bile acid sequestrants, can increase serum TG concentrations.  Lipid parameters, including TG levels and non-HDL-C, should be obtained before starting colesevelam and periodically thereafter.  Caution should be exercised when treating patients with TG levels greater than 300 mg/dL.  Colesevelam should be discontinued if TG levels exceed 500 mg/dL or if the patient develops hypertriglyceridemia-induced pancreatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41786, 25347, 'Colesevelam', 'Hyperlipoproteinemias', 'The manufacturer considers the use of colesevelam to be contraindicated in patients with TG levels >500 mg/dL.  Colesevelam, like other bile acid sequestrants, can increase serum TG concentrations.  Lipid parameters, including TG levels and non-HDL-C, should be obtained before starting colesevelam and periodically thereafter.  Caution should be exercised when treating patients with TG levels greater than 300 mg/dL.  Colesevelam should be discontinued if TG levels exceed 500 mg/dL or if the patient develops hypertriglyceridemia-induced pancreatitis.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41787, 14117, 'Colesevelam', 'Phenylketonurias', 'Questran Light and LoCholest Light (brands of cholestyramine) contain 16.8 mg and 22.4 mg of phenylalanine, respectively, per each dose.  Flavored Colestid (brand of colestipol) contains 18.2 mg of phenylalanine per each 7.5-gram dose.  WELCHOL (brand name of colesevelam) for Oral Suspension contains 13.5 mg phenylalanine per 1.875 gram dose and 27 mg phenylalanine per 3.75 gram dose.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).  Regular Colestid, Questran and LoCholest do not contain phenylalanine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41788, 16275, 'Colesevelam', 'Phenylketonurias', 'Questran Light and LoCholest Light (brands of cholestyramine) contain 16.8 mg and 22.4 mg of phenylalanine, respectively, per each dose.  Flavored Colestid (brand of colestipol) contains 18.2 mg of phenylalanine per each 7.5-gram dose.  WELCHOL (brand name of colesevelam) for Oral Suspension contains 13.5 mg phenylalanine per 1.875 gram dose and 27 mg phenylalanine per 3.75 gram dose.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).  Regular Colestid, Questran and LoCholest do not contain phenylalanine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41789, 25347, 'Colesevelam', 'Phenylketonurias', 'Questran Light and LoCholest Light (brands of cholestyramine) contain 16.8 mg and 22.4 mg of phenylalanine, respectively, per each dose.  Flavored Colestid (brand of colestipol) contains 18.2 mg of phenylalanine per each 7.5-gram dose.  WELCHOL (brand name of colesevelam) for Oral Suspension contains 13.5 mg phenylalanine per 1.875 gram dose and 27 mg phenylalanine per 3.75 gram dose.  The phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e.  phenylketonurics).  Regular Colestid, Questran and LoCholest do not contain phenylalanine.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41790, 14117, 'Colesevelam', 'Malabsorption Syndromes', 'Bile acid sequestrants, including colesevelam may decrease the absorption of fat-soluble vitamins A, D, E, and K.  Caution should be exercised when treating patients with a susceptibility to deficiencies of vitamin K (e.g., patients on warfarin, patients with malabsorption syndromes) or other fat-soluble vitamins.  The manufacturer recommends to instruct patients taking colesevelam and oral vitamin supplementation to take their vitamins at least 4 hours prior to colesevelam.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41791, 16275, 'Colesevelam', 'Malabsorption Syndromes', 'Bile acid sequestrants, including colesevelam may decrease the absorption of fat-soluble vitamins A, D, E, and K.  Caution should be exercised when treating patients with a susceptibility to deficiencies of vitamin K (e.g., patients on warfarin, patients with malabsorption syndromes) or other fat-soluble vitamins.  The manufacturer recommends to instruct patients taking colesevelam and oral vitamin supplementation to take their vitamins at least 4 hours prior to colesevelam.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41792, 25347, 'Colesevelam', 'Malabsorption Syndromes', 'Bile acid sequestrants, including colesevelam may decrease the absorption of fat-soluble vitamins A, D, E, and K.  Caution should be exercised when treating patients with a susceptibility to deficiencies of vitamin K (e.g., patients on warfarin, patients with malabsorption syndromes) or other fat-soluble vitamins.  The manufacturer recommends to instruct patients taking colesevelam and oral vitamin supplementation to take their vitamins at least 4 hours prior to colesevelam.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41793, 13724, 'Alfuzosin', 'Hepatic Insufficiency', 'Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment (Child Pugh B and C).  The pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment and caution should be exercised if it is administered to such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41794, 15074, 'Alfuzosin', 'Hepatic Insufficiency', 'Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment (Child Pugh B and C).  The pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment and caution should be exercised if it is administered to such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41795, 25400, 'Alfuzosin', 'Hepatic Insufficiency', 'Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment (Child Pugh B and C).  The pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment and caution should be exercised if it is administered to such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41796, 29722, 'Alfuzosin', 'Hepatic Insufficiency', 'Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment (Child Pugh B and C).  The pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment and caution should be exercised if it is administered to such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41797, 29723, 'Alfuzosin', 'Hepatic Insufficiency', 'Alfuzosin is contraindicated for use in patients with moderate or severe hepatic impairment (Child Pugh B and C).  The pharmacokinetics of alfuzosin have not been studied in patients with mild hepatic impairment and caution should be exercised if it is administered to such patients.', '3', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41798, 13724, 'Alfuzosin', 'Long QT Syndrome', 'Alfuzosin should be used with caution in patients with acquired or congenital QT prolongation, or who are taking medications that prolong the QT interval.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41799, 15074, 'Alfuzosin', 'Long QT Syndrome', 'Alfuzosin should be used with caution in patients with acquired or congenital QT prolongation, or who are taking medications that prolong the QT interval.', '2', '', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (41800, 25400, 'Alfuzosin', 'Long QT Syndrome', 'Alfuzosin should be used with caution in patients with acquired or congenital QT prolongation, or who are taking medications that prolong the QT interval.', '2', '', 'DDInter', 0);
